StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.24+0.24 (+12.00%)

Close on Nov 18, 2026Market cap $101.35MP/E –Yield –

Genelux net income

Net income is the profit left for shareholders after every expense, interest and tax.

Genelux's net income for the twelve months ending Jun 30, 2026 was -$35.60M. For fiscal 2025 it was -$32.15M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.15M–
FY2024Dec 31, 2024-$29.87M–
FY2023Dec 31, 2023-$28.30M–
FY2022Dec 31, 2022-$5.21M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.47M–
Q1 FY2026Mar 31, 2026-$8.93M–
Q4 FY2025Dec 31, 2025-$9.25M–
Q3 FY2025Sep 30, 2025-$7.95M–
Q2 FY2025Jun 30, 2025-$7.46M–
Q1 FY2025Mar 31, 2025-$7.49M–
Q4 FY2024Dec 31, 2024-$8.98M–
Q3 FY2024Sep 30, 2024-$6.47M–
Q2 FY2024Jun 30, 2024-$6.58M–
Q1 FY2024Mar 31, 2024-$7.85M–
Q4 FY2023Dec 31, 2023-$6.77M–
Q3 FY2023Sep 30, 2023-$5.35M-208.9%
Q2 FY2023Jun 30, 2023-$5.82M–
Q1 FY2023Mar 31, 2023-$10.36M–
Q4 FY2022Dec 31, 2022-$3.50M–
Q3 FY2022Sep 30, 2022$4.91M–
Q2 FY2022Jun 30, 2022-$2.82M–
Q1 FY2022Mar 31, 2022-$3.80M–

More Genelux figures

See a number that looks wrong?